A carregar...
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
Vascular endothelial growth factor (VEGF)-neutralizing therapy with bevacizumab has become increasingly important for treating colorectal cancer. It was demonstrated that second-line chemotherapy together with bevacizumab after disease progression (PD) on first-line therapy including bevacizumab sho...
Na minha lista:
| Publicado no: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4933557/ https://ncbi.nlm.nih.gov/pubmed/27350037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2016.4902 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|